A decade of antimicrobial susceptibilities at the University of Kentucky Hospital

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 596-604

  Rapp, Robert P ^a   Ribes, Julie A ^a   Overman, Sue B ^a   Darkow, Theodore E ^a   Evans, Martin E ^a   Da Camara, Carlos C ^a   Marcotte, Alain ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Antimicrobial agents; Susceptibility

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIINFECTIVE AGENT; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; METICILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; TOBRAMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; UNIVERSITY HOSPITAL;

EID: 0036205467     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A249     Document Type: Article

References (50)

1. Antimicrobial resistance: A plan of action for community practice
2. Revisiting emerging infectious diseases: The unfinished agenda
3. The impact of hospital-acquired bloodstream infections
4. Antimicrobial-drug resistance
5. Intercontinental spread of a new antibiotic resistance gene on an epidemic plasmid
6. Control of endemic methicillin-resistant Staphylococcus aureus
7. Examination of healthcare resource utilization associated with the treatment of infections caused by susceptible (S) and non-susceptible (NS) isolates of Streptococcus pneumoniae (SPN)
8. Attributable mortality rate and duration of hospital stay associated with enterococcal bacteremia
9. Poststernotomy mediastinitis due to Staphylococcus aureus: Comparison of methicillin-resistant and methicillin-susceptible cases
10. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
11. Antimicrobial resistance: A worldwide problem for health care institutions
12. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria
13. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting
14. Recommendation for preventing the spread of vancomycin resistance
15. Increasing threat of gram-negative bacteria
16. Antipseudomonal antibiotics
17. Bacterial antibiotic efflux systems of medical importance
18. Polymyxin B sulfate and colistin: Old antibiotics for emerging multiresistant gram-negative bacteria
19. Extended-spectrum β-lactamases: The role of inhibitors in therapy
20. Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY antimicrobial surveillance program
21. Nosocomial outbreak due to multiresistant strain of Pseudomonas aeruginosa P12: Efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance
22. Successful interventions for gram-negative resistance to extended-spectrum β-lactam antibiotics
23. Association of antibiotic utilization measures and contol of multiple-drug resistance in Klebsiella pneumoniae
24. Evidence of interhospital transmission of extended-spectrum beta-lactam-resistant Klebsiella pneumoniae in the United States, 1986-1993
25. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: Implications for the clinical microbiology laboratory
26. Enterobacter spp.: Pathogens poised to flourish at the turn of the century
27. Inducible beta-lactamases: Clinical and epidemiologic implications for use of newer cephalosporins
28. Control of an outbreak of infection due to extended-spectrum beta-lactamase-producing Escherichia coli in a liver transplantation unit
29. Detection of beta-lactamase-mediated resistance
30. Therapeutic challenges associated with extended-spectrum, beta-lacatamase-producing Escherichia coli and Klebsiella pneumoniae
31. Evolving antimicrobial chemotherapy for Staphylococcus aureus infections: Our backs to the wall
32. Beta-lactamases
33. Surveillance of antimicrobial use and antimicrobial resistance in United States hospital: Project ICARE Phase 2
34. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999
35. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY antimicrobial surveillance program, 1997-1999
36. The properties and mec A gene of the methicillin-resistant Staphylococcus aureus isolated in Fukushima Medical College Hospital
37. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
38. Trimethoprim-sulfamethoxazole compared to vancomycin for the treatment of Staphylococcus aureus infection
39. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
40. Staphylococcus aureus with reduced susceptibility to vancomycin: Illinois, 1999
41. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance
42. Vancomycin-intermediate and resistant Staphylococcus aureus: What the infectious disease specialist needs to know
43. Appropriate use of antimicrobials for drug-resistant pneumonia: Focus on the significance of beta-lactam-resistant Streptococcus pneumoniae
44. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999